Blinding the monocytes to protect the heart

Circulation

Volumn 127, Issue 20, 2013, Pages 2006-2008

  Charo, Israel F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOXYGENASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; SMALL INTERFERING RNA;

ARTERY LIGATION; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR INFLAMMATION; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY; EDITORIAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INFLAMMATION; MONOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ATHEROSCLEROSIS; EDITORIALS;

ANIMALS; ATHEROSCLEROSIS; FEMALE; GENE TARGETING; MONOCYTES; MYOCARDIAL INFARCTION; RECEPTORS, CCR2; RNA INTERFERENCE; WOUND HEALING;

EID: 84877948839     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.003045     Document Type: Editorial

References (27)

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325.
2. Galkina E, Ley K. Immune and infammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165-197.
3. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
4. Ridker PM. Testing the infammatory hypothesis of atherothrombosis: scientifc rationale for the Cardiovascular Infammation Reduction Trial (CIRT). J Thromb Haemost. 2009;7(suppl 1):332-339.
5. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-infammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605.
6. Gerrity RG. The role of the monocyte in atherogenesis, I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181-190.
7. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the nonhuman primate, I: changes that lead to fatty streak formation. Arteriosclerosis. 1984;4:323-340.
8. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local expression of infammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb. 1994;1(suppl 1):10-13.
9. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modifed low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134-5138.
10. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Molecular cloning and functional expression of two monocyte chemoat-tractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci U S A. 1994;91:2752-2756.
11. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897.
12. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-defcient mice. Mol Cell. 1998;2:275-281.
13. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1506-1516.
14. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953-964.
15. Carlin LM, Stamatiades EG, Auffray C, Hanna RN, Glover L, Vizcay-Barrena G, Hedrick CC, Cook HT, Diebold S, Geissmann F. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell. 2013;153:362-375.
16. Majmudar M, Keliher E, Heidt T, Leuschner F, Truelove J, Sena BF, Gorbatov R, Iwamoto Y, Dutta P, Wojtkiewicz G, Courties G, Sebas M, Borodovsky A, Fitzgerald K, Nolte MW, Dickneite G, Chen JW, Anderson DG, Swirski FK, Weissleder R, Nahrendorf M. Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation. 2013;127:2038-2046.
17. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204:3037-3047.
18. Leuschner F, Rauch PJ, Ueno T, Gorbatov R, Marinelli B, Lee WW, Dutta P, Wei Y, Robbins C, Iwamoto Y, Sena B, Chudnovskiy A, Panizzi P, Keliher E, Higgins JM, Libby P, Moskowitz MA, Pittet MJ, Swirski FK, Weissleder R, Nahrendorf M. Rapid monocyte kinetics in acute myocar-dial infarction are sustained by extramedullary monocytopoiesis. J Exp Med. 2012;209:123-137.
19. Si Y, Tsou CL, Croft K, Charo IF. CCR2 mediates hematopoietic stem and progenitor cell traffcking to sites of infammation in mice. J Clin Invest. 2010;120:1192-1203.
20. Rosenbaum D, Millon A, Fayad ZA. Molecular imaging in atherosclerosis: FDG PET. Curr Atheroscler Rep. 2012;14:429-437.
21. Tardif JC, L'allier PL, Ibrahim R, Grégoire JC, Nozza A, Cossette M, Kouz S, Lavoie MA, Paquin J, Brotz TM, Taub R, Pressacco J. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010;3:298-307.
22. Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, Lee KM, Kim JI, Markmann JF, Marinelli B, Panizzi P, Lee WW, Iwamoto Y, Milstein S, Epstein-Barash H, Cantley W, Wong J, Cortez-Retamozo V, Newton A, Love K, Libby P, Pittet MJ, Swirski FK, Koteliansky V, Langer R, Weissleder R, Anderson DG, Nahrendorf M. Therapeutic siRNA silencing in infammatory monocytes in mice. Nat Biotechnol. 2011;29:1005-1010.
23. Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, Wyant T, Davidson M; MLN1202 Study Group. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011;107:906-911.
24. Hanefeld M, Schell E, Gouni-Berthold I, Melichar M, Vesela I, Johnson D, Miao S, Sullivan T, Jaen J, Schall T, Bekker P; CCX140-B Diabetes Study Group. Orally-administered chemokine receptor CCR2 antagonist CCX140-B in type 2 diabetes: a pilot double-blind, randomized clinical trial. Diabetes Metab Rev. 2012;3:1-8.
25. Johnson GJ, Griggs TR, Badimon L. The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis: analysis and recommendations: on behalf of the Subcommittee on Animal, Cellular and Molecular Models of Thrombosis and Haemostasis of the Scientifc and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1999;81:835-843.
26. Tall AR, Yvan-Charvet L, Westerterp M, Murphy AJ. Cholesterol effux: a novel regulator of myelopoiesis and atherogenesis. Arterioscler Thromb Vasc Biol. 2012;32:2547-2552.
27. Serbina NV, Pamer EG. Coordinating innate immune cells to optimize microbial killing. Immunity. 2008;29:672-674.